Observational studyBMC neurology2026
Integrating serum neurotrophin profiles and quantitative EEG for predicting motor outcomes in acute ischemic stroke.
Observational study in BMC neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesAccurate prediction of motor recovery after acute ischemic stroke remains challenging. We investigated whether integrating serum neurotrophin profiles with quantitative electroencephalography (qEEG) parameters enhances predictive accuracy for 6-month motor outcomes beyond conventional clinical predictors.
methodsThis prospective observational study enrolled 108 patients with first-ever acute ischemic stroke admitted within 24 h of symptom onset between December 2023 and December 2024. Serum brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) were measured at admission (Day 1) and Day 3. qEEG recording was performed within 72 h, with calculation of delta-alpha ratio (DAR), delta-theta/alpha-beta ratio (DTABR), and brain symmetry index (BSI). The primary outcome was motor function at 6 months assessed by Fugl-Meyer Assessment upper extremity score (FMA-UE), dichotomized as good (FMA-UE ≥ 50) or poor (FMA-UE < 50) outcome. Multivariate logistic regression models were developed and compared using receiver operating characteristic analysis.
resultsAt 6-month follow-up, 64 patients (59.3%) achieved good motor outcome. Patients with good outcome demonstrated significantly higher BDNF levels at Day 1 (14.05 ± 5.30 vs. 10.97 ± 4.58 ng/mL, P = 0.002) and lower DAR (median 0.42 [IQR 0.22-0.61] vs. 0.83 [0.56-1.16], P < 0.001) compared with poor outcome group. The clinical-only model (Model 1: comprising age, sex, NIHSS, ASPECTS, reperfusion therapy, and diabetes mellitus) achieved a cross-validated area under the receiver operating characteristic curve (AUC) of 0.884 (95% CI: 0.862-0.907). Addition of neurotrophin biomarkers improved cross-validated AUC to 0.903 (95% CI: 0.877-0.928), while addition of qEEG parameters yielded cross-validated AUC of 0.922 (95% CI: 0.901-0.943). The combined model integrating clinical variables, neurotrophins, and qEEG achieved the highest discriminative performance (cross-validated AUC = 0.930, 95% CI: 0.908-0.952) with sensitivity of 92.2% and specificity of 93.2% at the optimal threshold.
conclusionsA multimodal prediction model combining serum neurotrophin profiles and qEEG parameters provides incremental improvement in prognostic accuracy for motor outcomes in acute ischemic stroke, though differences in discriminative performance between models did not reach statistical significance in this sample. This integrated approach may facilitate individualized rehabilitation planning and resource allocation in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.